{"name":"Orca Biosystems, Inc.","slug":"orca-biosystems-inc","ticker":"","exchange":"","domain":"orcabiosystems.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Orca-T","genericName":"Orca-T","slug":"orca-t","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"Orca-T","genericName":"Orca-T","slug":"orca-t","phase":"phase_3","mechanism":"Orca-T is a monoclonal antibody that targets the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNMl9ESXIzS0x0bVpsMGhFR1lMeUU4QmozSUw5dTJvWndIUnZDT002dzFfczFUY0dOVElKNGFsMTRVLVpXZ1A1UUlkX2czb05TQWxkYjdPdlFmZUFPS296cnFMc04tbnBoRjE2Y05LSHBBa29nS1ZIeUJhd1JKMzRlUlpXZndzcy1lLXdnTXlZSWNCUVk5OXRiOWpB?oc=5","date":"2025-05-12","type":"pipeline","source":"Business Wire","summary":"Orca Bio Announces Leadership Updates - Business Wire","headline":"Orca Bio Announces Leadership Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPZHFFWmUyakloQjlrTDVjMktyOF8yTHowcl8xbG5zV3JmNkNTUmJTX3pUMFBNUkw5VlJ5ZmVtLWdoUU8yazhfVUFkM3ozU2VucUxsYzhPalFRRzRSaXMzWHZGbGFDSVZ0eWxBdElBQWxQZXNVTkw2RFlEMXRyUUw2WlJhd2VOcnpFR2pPTDh5QklNSWIxZ054QzdXREs5R29CRWk3Mi01S2x6dFRjS3c?oc=5","date":"2022-09-08","type":"pipeline","source":"The Business Journals","summary":"Why a cutting-edge cancer cell therapy company picked Sacramento for a key manufacturing site - The Business Journals","headline":"Why a cutting-edge cancer cell therapy company picked Sacramento for a key manufacturing site","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}